Cox regression of risk factors on OS in lung cancer
| Parameter . | OS . | |||
|---|---|---|---|---|
| UVA . | MVA . | |||
| OS HR (95% CI) . | P value . | OS HR (95% CI) . | P value . | |
| Age ≥60 y | 1.65 (1.12-2.44) | .012 | 1.73 (1.15-2.59) | .008 |
| Male sex | 1.48 (1.09-2.02) | .013 | 1.37 (0.98-1.92) | .066 |
| Race | ||||
| White | Ref | NA | ||
| Black | 0.63 (0.33-1.20) | .160 | ||
| Other/unknown | NE | |||
| Ethnicity | ||||
| Non-Hispanic | Ref | |||
| Hispanic | 0.95 (0.69-1.29) | .725 | NA | |
| Unknown | NE | |||
| Tobacco history | ||||
| None/never used | Ref | |||
| Any current/prior use | 2.26 (1.41-3.60) | <.001 | 1.43 (0.86-2.38) | .171 |
| Baseline WBC ≥11 × 109/L | 2.33 (1.71-3.19) | <.001 | 1.72 (1.22-2.42) | .002 |
| Baseline Hb <10 g/dL | 2.73 (1.87-4.01) | <.01 | 1.84 (1.19-2.83) | .006 |
| Baseline Plt ≥350 × 109/L | 1.53 (1.11-2.11) | .009 | 0.92 (0.64-1.21) | .652 |
| BMI, kg/m2 | ||||
| <18.5 | 1.36 (0.78-2.36) | .282 | NA | |
| 18.5-24.9 | Ref | |||
| ≥25-25.9 | 0.60 (0.44-0.82) | .002 | NA | |
| Unknown | NE | |||
| KS | ||||
| 1-2 | Ref | NA | ||
| 3-4 | 2.62 (1.86-3.82) | <.001 | 1.87 (1.30-2.70) | <.001 |
| Lung cancer type | ||||
| AC | Ref | NA | ||
| SCC | 1.62 (1.10-2.38) | .014 | 0.97 (0.62-1.51) | .896 |
| NSCLC, NOS | 1.77 (0.97-3.23) | .065 | 1.49 (0.78-2.85) | .226 |
| SCLC | 1.56 (1.03-2.36) | .036 | 0.88 (0.53-1.47) | .622 |
| Unknown | NE | NE | ||
| AJCC stage | ||||
| I-II | Ref | Ref | ||
| III-IV | 13.69 (4.37-42.90) | <.001 | 4.17 (1.24-14.07) | .021 |
| Unknown | 1.73 (0.29-10.35) | .536 | 1.02 (0.16-6.46) | .985 |
| Therapy type | ||||
| Chemotherapy | 0.96 (0.44-2.12) | .929 | NA | |
| Chemoimmunotherapy | 1.46 (0.68-3.14) | .333 | ||
| Targeted therapy | 0.40 (0.14-1.09) | .074 | ||
| Radiation therapy | 1.24 (0.92-1.69) | .159 | ||
| Surgery | 0.07 (0.03-0.18) | <.001 | 0.18 (0.07-0.46) | <.001 |
| VTE, yes (total) | 2.05 (1.37-3.06) | <.001 | 1.86 (1.22-2.3) | .004 |
| Parameter . | OS . | |||
|---|---|---|---|---|
| UVA . | MVA . | |||
| OS HR (95% CI) . | P value . | OS HR (95% CI) . | P value . | |
| Age ≥60 y | 1.65 (1.12-2.44) | .012 | 1.73 (1.15-2.59) | .008 |
| Male sex | 1.48 (1.09-2.02) | .013 | 1.37 (0.98-1.92) | .066 |
| Race | ||||
| White | Ref | NA | ||
| Black | 0.63 (0.33-1.20) | .160 | ||
| Other/unknown | NE | |||
| Ethnicity | ||||
| Non-Hispanic | Ref | |||
| Hispanic | 0.95 (0.69-1.29) | .725 | NA | |
| Unknown | NE | |||
| Tobacco history | ||||
| None/never used | Ref | |||
| Any current/prior use | 2.26 (1.41-3.60) | <.001 | 1.43 (0.86-2.38) | .171 |
| Baseline WBC ≥11 × 109/L | 2.33 (1.71-3.19) | <.001 | 1.72 (1.22-2.42) | .002 |
| Baseline Hb <10 g/dL | 2.73 (1.87-4.01) | <.01 | 1.84 (1.19-2.83) | .006 |
| Baseline Plt ≥350 × 109/L | 1.53 (1.11-2.11) | .009 | 0.92 (0.64-1.21) | .652 |
| BMI, kg/m2 | ||||
| <18.5 | 1.36 (0.78-2.36) | .282 | NA | |
| 18.5-24.9 | Ref | |||
| ≥25-25.9 | 0.60 (0.44-0.82) | .002 | NA | |
| Unknown | NE | |||
| KS | ||||
| 1-2 | Ref | NA | ||
| 3-4 | 2.62 (1.86-3.82) | <.001 | 1.87 (1.30-2.70) | <.001 |
| Lung cancer type | ||||
| AC | Ref | NA | ||
| SCC | 1.62 (1.10-2.38) | .014 | 0.97 (0.62-1.51) | .896 |
| NSCLC, NOS | 1.77 (0.97-3.23) | .065 | 1.49 (0.78-2.85) | .226 |
| SCLC | 1.56 (1.03-2.36) | .036 | 0.88 (0.53-1.47) | .622 |
| Unknown | NE | NE | ||
| AJCC stage | ||||
| I-II | Ref | Ref | ||
| III-IV | 13.69 (4.37-42.90) | <.001 | 4.17 (1.24-14.07) | .021 |
| Unknown | 1.73 (0.29-10.35) | .536 | 1.02 (0.16-6.46) | .985 |
| Therapy type | ||||
| Chemotherapy | 0.96 (0.44-2.12) | .929 | NA | |
| Chemoimmunotherapy | 1.46 (0.68-3.14) | .333 | ||
| Targeted therapy | 0.40 (0.14-1.09) | .074 | ||
| Radiation therapy | 1.24 (0.92-1.69) | .159 | ||
| Surgery | 0.07 (0.03-0.18) | <.001 | 0.18 (0.07-0.46) | <.001 |
| VTE, yes (total) | 2.05 (1.37-3.06) | <.001 | 1.86 (1.22-2.3) | .004 |